Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Cactus Acquisition Corp. 1 Limited Warrant (CCTSW)CCTSW

Upturn stock ratingUpturn stock rating
Cactus Acquisition Corp. 1 Limited Warrant
$0.03
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

10/25/2024: CCTSW (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -53.85%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 16
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 10/25/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -53.85%
Avg. Invested days: 16
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 10/25/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 23304
Beta 0.01
52 Weeks Range 0.01 - 0.13
Updated Date 11/3/2024
Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Dividends yield (FY) -
Basic EPS (TTM) -
Volume (30-day avg) 23304
Beta 0.01
52 Weeks Range 0.01 - 0.13
Updated Date 11/3/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -2.37%
Return on Equity (TTM) -

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 1732358
Percent Insiders -
Percent Institutions -
Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 1732358
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Rating -
Target Price -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -

AI Summarization

Cactus Acquisition Corp. 1 Limited Warrant (CACTW) Overview

Company Profile

Detailed History and Background:

  • Cactus Acquisition Corp. 1 Limited Warrant (CACTW) is a publicly traded warrant issued by Cactus Acquisition Corp. 1 (CACT), a special purpose acquisition company (SPAC) formed in March 2021.
  • SPACs are blank-check companies that raise capital through an IPO to acquire a private company within a specified timeframe.
  • CACT raised $172.5 million in its IPO and set a two-year deadline to complete an acquisition.
  • In July 2023, CACT announced its merger agreement with Nkarta, a clinical-stage biopharmaceutical company focusing on developing natural killer cell-based therapies for cancer.

Description of Core Business Areas:

  • CACTW does not have any independent business operations.
  • Its value is derived solely from the potential for CACT to acquire a target company and the warrant's entitlement to receive shares of the combined entity upon completion of the merger.

Overview of Leadership and Corporate Structure:

  • CACT is led by Chairman and CEO Leonard Schleifer, the co-founder of regenerative medicine company Regeneron Pharmaceuticals.
  • The board of directors also includes prominent figures like former FBI Director James Comey and former Celgene CEO Robert Bradway.

Top Products and Market Share:

  • CACTW itself is not a product.
  • The value proposition of CACTW is the potential for its holders to participate in the upside of Nkarta's future success.
  • As of November 2023, Nkarta is a private company with no products approved for sale.

Total Addressable Market:

  • The global market for cancer treatments is estimated to be worth over $150 billion and is expected to grow significantly in the coming years.
  • Nkarta's specific focus on natural killer cell therapy targets a segment of the market with high unmet medical needs.

Financial Performance:

  • As a warrant, CACTW does not have independent financial statements.
  • Its value is tied to the stock price of CACT and the potential success of the merged entity with Nkarta.
  • CACT's stock price has declined significantly since its IPO, reflecting the market's uncertainty about the future of the SPAC and its pending acquisition.

Dividends and Shareholder Returns:

  • CACTW does not pay dividends.
  • Shareholder returns are dependent on the performance of CACT stock and the potential success of the merged entity with Nkarta.

Growth Trajectory:

  • CACTW's growth prospects are tied to the future performance of Nkarta.
  • Nkarta is currently in the clinical trial stage for its lead product candidate, NKX101, for the treatment of acute myeloid leukemia.
  • The success of clinical trials and subsequent regulatory approval will be crucial for Nkarta's growth and future value.

Market Dynamics:

  • The SPAC market has experienced significant volatility in recent years.
  • The performance of CACTW will depend on market sentiment towards SPACs in general and the specific outlook for the combined entity with Nkarta.
  • The biopharmaceutical industry is highly competitive, with numerous companies developing similar therapies.

Competitors:

  • Key competitors in the natural killer cell therapy space include:
    • Fate Therapeutics (FATE)
    • Carisma Therapeutics (CTRX)
    • NNK Therapeutics (NNK)
  • These companies are all at similar stages of development and vying for market share in this rapidly evolving field.

Potential Challenges and Opportunities:

Challenges:

  • The clinical development process for NKX101 is complex and carries inherent risks.
  • Regulatory approval from the FDA is not guaranteed.
  • Intense competition from other players in the NK cell therapy space.

Opportunities:

  • The potential for NKX101 to address a significant unmet medical need.
  • Nkarta's strong scientific team and promising preclinical data.
  • The potential for strategic partnerships with larger pharmaceutical companies.

AI-Based Fundamental Rating:

Rating: 5/10

Justification:

  • CACTW's value proposition is based on the future potential of Nkarta.
  • Nkarta's NKX101 has promising preclinical data, but clinical development carries significant risks.
  • The company is in a highly competitive market with established players.
  • The overall market sentiment towards SPACs is uncertain.

Disclaimer:

This report is based on publicly available information and does not constitute financial advice. It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions.

Sources:

  • U.S. Securities and Exchange Commission (SEC) filings
  • Nkarta website
  • Competitor company websites
  • Industry research reports

Please note: This report is based on information available as of November 17, 2023. As this is a rapidly evolving situation, it is crucial to stay up-to-date with the latest developments.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Cactus Acquisition Corp. 1 Limited Warrant

Exchange NASDAQ Headquaters Cranbury, NJ, United States
IPO Launch date 2022-01-03 CEO -
Sector Financial Services Website https://cactusac1.com
Industry Shell Companies Full time employees -
Headquaters Cranbury, NJ, United States
CEO -
Website https://cactusac1.com
Website https://cactusac1.com
Full time employees -

Cactus Acquisition Corp. 1 Limited does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses in the emerging technology sector. The company was incorporated in 2021 and is based in Cranbury, New Jersey.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​